Table 3.
Odds ratios and confidence intervals of different patient groups.
| Risk Factor (n Patients) | |||||||
|---|---|---|---|---|---|---|---|
| Diseased | not Diseased | ||||||
| Groups | Antigen | yes | no | yes | no | OR | 95% CI |
| asymptomatic (n = 17) vs. atrophic (n = 17) | CagA | 14 | 3 | 8 | 9 | 5.3 | 1.1–25.2 |
| VacA m1 | 8 | 9 | 2 | 15 | 6.7 | 1.2–38.6 | |
| HP0231 | 10 | 7 | 6 | 11 | 2.6 | 0.7–10.5 | |
| asymptomatic (n = 40) vs. intestinal metaplasia (n = 40) | CagA | 36 | 4 | 24 | 16 | 6.0 | 1.8–20.2 |
| VacA m1 | 9 | 31 | 6 | 34 | 1.7 | 0.5–5.2 | |
| HP0231 | 14 | 26 | 19 | 21 | 0.6 | 0.2–1.5 | |
| asymptomatic (n = 51) vs. premalignant changes (n = 57) | CagA | 50 | 7 | 28 | 23 | 5.9 | 2.2–15.4 |
| VacA m1 | 17 | 40 | 8 | 43 | 2.3 | 0.9–5.9 | |
| HP0231 | 24 | 33 | 24 | 27 | 0.8 | 0.4–1.8 | |
| asymptomatic (n = 14) vs. ulcer (n = 14) | CagA | 10 | 4 | 7 | 7 | 2.5 | 0.5–11.9 |
| VacA m1 | 3 | 11 | 12 | 2 | 1.6 | 0.2–11.7 | |
| HP0231 | 5 | 9 | 7 | 7 | 0.6 | 0.1–2.5 | |
The samples of the compared groups were matched for age and gender. The atrophic and intestinal metaplasia status were taken together as “premalignant changes” and also compared to the asymptomatic group of samples.